Vish Seshadri, Abeona CEO
After delay, Abeona aims for fall FDA submission for rare skin condition cell therapy
In June, Abeona pushed back the timeline for its application to the FDA for approval of a rare genetic skin cell therapy. At the time …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
